Detection of aberrant transcription of major histocompatibility complex class II antigen presentation genes in chronic lymphocytic leukaemia identifies HLA-DOA mRNA as a prognostic factor for survival.

Standard

Detection of aberrant transcription of major histocompatibility complex class II antigen presentation genes in chronic lymphocytic leukaemia identifies HLA-DOA mRNA as a prognostic factor for survival. / Souwer, [Unbekannt]; Yuri, [Unbekannt]; Chamuleau, [Unbekannt]; Martine, E D; Loosdrecht, van de; Arjan, A; Tolosa, Eva; Eva, [Unbekannt]; Jorritsma, [Unbekannt]; Tineke, [Unbekannt]; Muris, [Unbekannt]; Jettie, J F; Poppel, Dinnissen-van; Marion, J; Snel, [Unbekannt]; Sander, N; Corput, van de; Lisette, [Unbekannt]; Ossenkoppele, [Unbekannt]; Gert, J; Meijer, [Unbekannt]; Chris, J L M; Neefjes, [Unbekannt]; Jacques, J; van Ham, Marieke.

in: BRIT J HAEMATOL, Jahrgang 145, Nr. 3, 3, 2009, S. 334-343.

Publikationen: SCORING: Beitrag in Fachzeitschrift/ZeitungSCORING: ZeitschriftenaufsatzForschungBegutachtung

Harvard

Souwer, U, Yuri, U, Chamuleau, U, Martine, ED, Loosdrecht, VD, Arjan, A, Tolosa, E, Eva, U, Jorritsma, U, Tineke, U, Muris, U, Jettie, JF, Poppel, D, Marion, J, Snel, U, Sander, N, Corput, VD, Lisette, U, Ossenkoppele, U, Gert, J, Meijer, U, Chris, JLM, Neefjes, U, Jacques, J & van Ham, M 2009, 'Detection of aberrant transcription of major histocompatibility complex class II antigen presentation genes in chronic lymphocytic leukaemia identifies HLA-DOA mRNA as a prognostic factor for survival.', BRIT J HAEMATOL, Jg. 145, Nr. 3, 3, S. 334-343. <http://www.ncbi.nlm.nih.gov/pubmed/19245431?dopt=Citation>

APA

Souwer, U., Yuri, U., Chamuleau, U., Martine, E. D., Loosdrecht, V. D., Arjan, A., Tolosa, E., Eva, U., Jorritsma, U., Tineke, U., Muris, U., Jettie, J. F., Poppel, D., Marion, J., Snel, U., Sander, N., Corput, V. D., Lisette, U., Ossenkoppele, U., ... van Ham, M. (2009). Detection of aberrant transcription of major histocompatibility complex class II antigen presentation genes in chronic lymphocytic leukaemia identifies HLA-DOA mRNA as a prognostic factor for survival. BRIT J HAEMATOL, 145(3), 334-343. [3]. http://www.ncbi.nlm.nih.gov/pubmed/19245431?dopt=Citation

Vancouver

Bibtex

@article{53cac25e27024f0bb010d260acf033ae,
title = "Detection of aberrant transcription of major histocompatibility complex class II antigen presentation genes in chronic lymphocytic leukaemia identifies HLA-DOA mRNA as a prognostic factor for survival.",
abstract = "In human B cells, effective major histocompatibility complex (MHC) class II-antigen presentation depends not only on MHC class II, but also on the invariant chain (CD74 or Ii), HLA-DM (DM) and HLA-DO (DO), the chaperones regulating the antigen loading process of MHC class II molecules. We analysed immediate ex vivo expression of HLA-DR (DR), CD74, DM and DO in B cell chronic lymphocytic leukaemia (B-CLL). Real-time reverse transcription polymerase chain reaction demonstrated a highly significant upregulation of DRA, CD74, DMB, DOA and DOB mRNA in purified malignant cells compared to B cells from healthy donors. The increased mRNA levels were not translated into enhanced protein levels but could reflect aberrant transcriptional regulation. Indeed, upregulation of DRA, DMB, DOA and DOB mRNA correlated with enhanced expression of class II transactivator (CIITA). In-depth analysis of the various CIITA transcripts demonstrated a significant increased activity of the interferon-gamma-inducible promoter CIITA-PIV in B-CLL. Comparison of the aberrant mRNA levels with clinical outcome identified DOA mRNA as a prognostic indicator for survival. Multivariate analysis revealed that the prognostic value of DOA mRNA was independent of the mutational status of the IGHV genes. Thus, aberrant transcription of DOA forms a novel and additional prognostic indicator for survival in B-CLL.",
author = "[Unbekannt] Souwer and [Unbekannt] Yuri and [Unbekannt] Chamuleau and Martine, {E D} and Loosdrecht, {van de} and A Arjan and Eva Tolosa and [Unbekannt] Eva and [Unbekannt] Jorritsma and [Unbekannt] Tineke and [Unbekannt] Muris and Jettie, {J F} and Dinnissen-van Poppel and J Marion and [Unbekannt] Snel and N Sander and Corput, {van de} and [Unbekannt] Lisette and [Unbekannt] Ossenkoppele and J Gert and [Unbekannt] Meijer and Chris, {J L M} and [Unbekannt] Neefjes and J Jacques and {van Ham}, Marieke",
year = "2009",
language = "Deutsch",
volume = "145",
pages = "334--343",
journal = "BRIT J HAEMATOL",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "3",

}

RIS

TY - JOUR

T1 - Detection of aberrant transcription of major histocompatibility complex class II antigen presentation genes in chronic lymphocytic leukaemia identifies HLA-DOA mRNA as a prognostic factor for survival.

AU - Souwer, [Unbekannt]

AU - Yuri, [Unbekannt]

AU - Chamuleau, [Unbekannt]

AU - Martine, E D

AU - Loosdrecht, van de

AU - Arjan, A

AU - Tolosa, Eva

AU - Eva, [Unbekannt]

AU - Jorritsma, [Unbekannt]

AU - Tineke, [Unbekannt]

AU - Muris, [Unbekannt]

AU - Jettie, J F

AU - Poppel, Dinnissen-van

AU - Marion, J

AU - Snel, [Unbekannt]

AU - Sander, N

AU - Corput, van de

AU - Lisette, [Unbekannt]

AU - Ossenkoppele, [Unbekannt]

AU - Gert, J

AU - Meijer, [Unbekannt]

AU - Chris, J L M

AU - Neefjes, [Unbekannt]

AU - Jacques, J

AU - van Ham, Marieke

PY - 2009

Y1 - 2009

N2 - In human B cells, effective major histocompatibility complex (MHC) class II-antigen presentation depends not only on MHC class II, but also on the invariant chain (CD74 or Ii), HLA-DM (DM) and HLA-DO (DO), the chaperones regulating the antigen loading process of MHC class II molecules. We analysed immediate ex vivo expression of HLA-DR (DR), CD74, DM and DO in B cell chronic lymphocytic leukaemia (B-CLL). Real-time reverse transcription polymerase chain reaction demonstrated a highly significant upregulation of DRA, CD74, DMB, DOA and DOB mRNA in purified malignant cells compared to B cells from healthy donors. The increased mRNA levels were not translated into enhanced protein levels but could reflect aberrant transcriptional regulation. Indeed, upregulation of DRA, DMB, DOA and DOB mRNA correlated with enhanced expression of class II transactivator (CIITA). In-depth analysis of the various CIITA transcripts demonstrated a significant increased activity of the interferon-gamma-inducible promoter CIITA-PIV in B-CLL. Comparison of the aberrant mRNA levels with clinical outcome identified DOA mRNA as a prognostic indicator for survival. Multivariate analysis revealed that the prognostic value of DOA mRNA was independent of the mutational status of the IGHV genes. Thus, aberrant transcription of DOA forms a novel and additional prognostic indicator for survival in B-CLL.

AB - In human B cells, effective major histocompatibility complex (MHC) class II-antigen presentation depends not only on MHC class II, but also on the invariant chain (CD74 or Ii), HLA-DM (DM) and HLA-DO (DO), the chaperones regulating the antigen loading process of MHC class II molecules. We analysed immediate ex vivo expression of HLA-DR (DR), CD74, DM and DO in B cell chronic lymphocytic leukaemia (B-CLL). Real-time reverse transcription polymerase chain reaction demonstrated a highly significant upregulation of DRA, CD74, DMB, DOA and DOB mRNA in purified malignant cells compared to B cells from healthy donors. The increased mRNA levels were not translated into enhanced protein levels but could reflect aberrant transcriptional regulation. Indeed, upregulation of DRA, DMB, DOA and DOB mRNA correlated with enhanced expression of class II transactivator (CIITA). In-depth analysis of the various CIITA transcripts demonstrated a significant increased activity of the interferon-gamma-inducible promoter CIITA-PIV in B-CLL. Comparison of the aberrant mRNA levels with clinical outcome identified DOA mRNA as a prognostic indicator for survival. Multivariate analysis revealed that the prognostic value of DOA mRNA was independent of the mutational status of the IGHV genes. Thus, aberrant transcription of DOA forms a novel and additional prognostic indicator for survival in B-CLL.

M3 - SCORING: Zeitschriftenaufsatz

VL - 145

SP - 334

EP - 343

JO - BRIT J HAEMATOL

JF - BRIT J HAEMATOL

SN - 0007-1048

IS - 3

M1 - 3

ER -